Peter Guzzo Joins Variational AI as Vice President, Head of Drug Discovery
Read more: Peter Guzzo Joins Variational AI as Vice President, Head of Drug DiscoveryVariational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced that Peter… Read More about Peter Guzzo Joins Variational AI as Vice President, Head of Drug Discovery
Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic
Read more: Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 TherapeuticVariational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced the company… Read More about Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic
Variational AI Secures $US3.5 Million in Seed Funding to Apply State-of-the-Art AI Platform to Generate Novel Small Molecule Therapeutics for Drug Development
Read more: Variational AI Secures $US3.5 Million in Seed Funding to Apply State-of-the-Art AI Platform to Generate Novel Small Molecule Therapeutics for Drug DevelopmentVariational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecules, today announced that it has… Read More about Variational AI Secures $US3.5 Million in Seed Funding to Apply State-of-the-Art AI Platform to Generate Novel Small Molecule Therapeutics for Drug Development
